Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Researcher Studies Ways to Cut Cardiovascular Disease Risk in Rheumatoid Arthritis Patients

Staff  |  Issue: June 2013  |  June 1, 2013

“I’m hopeful we’ll be able to inform rheumatologists about what roles are appropriate and help them develop a patient-centered approach to helping patients modify their CVD risk factors, whether that be [by] empowering primary care physicians with knowledge and having them manage these risks, or [having] the rheumatologists themselves actively engage in helping modify risks,” Dr. Bartels adds.

Determining the interventions that will help RA patients manage and modify CVD risk is the next step in Dr. Bartels’ research. She’s currently conducting an examination of RA visit notes and clinical data. Her plan is to couple that information with interviews of primary care physicians, rheumatologists, and patients to determine how engaged each group is in conversations around CVD risk and how patients envision optimal input from their treatment providers.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“We’ll be able to describe the relative impact of those different roles and patient preferences so that we can better partner with our patients to help them understand and manage their modifiable heart disease risks,” Dr. Bartels says.

For more information about the Bridge Funding Award and other Rheumatology Research Foundation awards and grants programs, visit www.rheumatology.org/Foundation or contact Damian Smalls at (404) 633-3777, or [email protected].

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Funding for this award was made possible in part through the financial support of the Arthritis Foundation.

Page: 1 2 | Single Page
Share: 

Filed under:From the College Tagged with:Cardiovascular diseasepatient communicationRARheumatoid arthritis

Related Articles

    Better Blood Pressure Screening Needed to Manage Cardiovascular Disease Risk in Rheumatoid Arthritis

    October 3, 2014

    Study finds hypertensive patients with RA less likely to be diagnosed with high blood pressure than non-RA patients

    Study Finds NSAIDs Raise Heart Disease Risk in Osteoarthritis Patients

    February 16, 2021

    In a controlled, large-cohort, longi­tudinal study from Canada, Atiquazzaman et al. found that use of non-steroidal anti-inflammatory drugs (NSAIDs) substantially contributes to increased cardiovascular disease risk among people with osteoarthritis (OA).1  This is the first study to evaluate the mediating role that NSAIDs play in the association between OA and cardiovascular disease (CVD), and the…

    Biomarkers, Genetic Clues to Higher Cardiovascular Disease Risk in Patients with Lupus

    April 20, 2017

    WASHINGTON, D.C.—Experts at the 2016 ACR/ARHP Annual Meeting session, Systemic Lupus Erythematosus—Clinical Aspects and Treatment IV: Biomarkers, reported on a number of recent studies showing advancement in our understanding of the disease mechanisms underlying systemic lupus erythematosus (SLE) that place these patients at risk for cardiovascular disease (CVD) and other comorbidities. Mechanisms of CVD Risk…

    Long-Term Benefits, Risks of Biologic Disease-Modifying Anti-Rheumatic Drugs in Patients with RA

    December 19, 2017

    Two decades have passed since the first biologic disease-modifying anti-rheumatic drug (bDMARD) was approved. Studies on the long-term use of biologics in different disease states, such as for cardiovascular disease (CVD) and malignancy, as well as for knee/hip replacement, reveal some encouraging news. In clinical trials, bDMARDs have been shown to increase the risk of…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences